Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Launches of Rebyota ® and Adstiladrin ® in United States provide major mid- to -long-term opportunities for the company to diversify into new therapeutic areas Significant changes to senior management, headed by new Chairman, Jean-Frédéric Paulsen, ensure Ferring is well-placed to maximise these opportunities #ProjectFamily Safe Birth to reduce maternal deaths wins recognition for Ferring in Fortune's ‘Change the World' list of companies with the greatest social impact SAINT-PREX, Switzerland, April 09, 2024 BUSINESS WIRE )--Ferring today published its 2023 Annual Report showing the company's annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million. The year marked a major turning-point for Ferring with the launch of two innovative first-in-class med
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Royalty Pharma Declares Second Quarter 2024 DividendGlobeNewswire
- Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
RPRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RPRX's page on the SEC website